Literature DB >> 33413565

Long non-coding RNA FAM83H-AS1 acts as a potential oncogenic driver in human ovarian cancer.

Xiaolei Yuan1, Ying Huang2, Man Guo1, Xiaowei Hu3, Peiling Li4.   

Abstract

OBJECTIVE: Ovarian cancer (OC) is one of the most aggressive women cancers with increasing incidence and mortality rates worldwide. Long non-coding RNAs (lncRNAs) could as major players in OC process. Although FAM83H antisense RNA1 (FAM83H-AS1) is demonstrated play an important roles in a many cancers, the detailed function and mechanism has not been reported in OC.
RESULTS: We integrated multiple kinds of bioinformatics approaches and experiments validated method to evaluate functions of FAM83H-AS1 in OC. Some differential expressed lncRNAs were identified between OC and normal control tissues. FAM83H-AS1 was one of most differentially expressed lncRNAs and up-regulated in multiple cancer types. Specially, expression of FAM83H-AS1 was higher in OC and showed difference in diverse stages. High FAM83H-AS1 expression is associated with worse pan-cancer and OC outcomes. FAM83H-AS1-centric network including lncRNA-miRNA, lncRNA-protein and lncRNA-mRNA ceRNA network were constructed to infer the function and mechanism of FAM83H-AS1. There were two methylation sites including cg01399317 and cg20519035 located at FAM83H-AS1. The methylation level of cg01399317 was correlated with gene expression of FAM83H-AS1. The expression level of FAM83H-AS1 was correlated with infiltration level of immune cell including macrophage, neutrphil and dendritic cell in OC patients. Lastly, qRT-PCR showed that the expression of FAM83H-AS1 was higher in OC tissues than normal control tissues.
CONCLUSION: Collectively, these results indicated that FAM83H-AS1 may act as an oncogenic driver and it may be a potential therapy target in OC.

Entities:  

Keywords:  Immune; Network; Ovarian cancer; Survival; lncRNA FAM83H-AS1

Year:  2021        PMID: 33413565      PMCID: PMC7792319          DOI: 10.1186/s13048-020-00756-y

Source DB:  PubMed          Journal:  J Ovarian Res        ISSN: 1757-2215            Impact factor:   4.234


  38 in total

1.  BRCA1 modulates the expression of hnRNPA2B1 and KHSRP.

Authors:  Manuela Santarosa; Laura Del Col; Alessandra Viel; Nicoletta Bivi; Chiara D'Ambrosio; Andrea Scaloni; Gianluca Tell; Roberta Maestro
Journal:  Cell Cycle       Date:  2010-12-01       Impact factor: 4.534

Review 2.  LncRNAs Coming of Age.

Authors:  Phillip Grote; Reinier A Boon
Journal:  Circ Res       Date:  2018-08-17       Impact factor: 17.367

Review 3.  Role of lncRNAs as Novel Biomarkers and Therapeutic Targets in Ovarian Cancer.

Authors:  Lu-Lu Fu; Chun-Jin Li; Ying Xu; Ling-Yun Li; Xu Zhou; Dan-Dan Li; Shu-Xiong Chen; Feng-Ge Wang; Xue-Ying Zhang; Lian-Wen Zheng
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2017       Impact factor: 1.807

4.  Cancer statistics, 2015.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-01-05       Impact factor: 508.702

Review 5.  Cancer immunotherapy using checkpoint blockade.

Authors:  Antoni Ribas; Jedd D Wolchok
Journal:  Science       Date:  2018-03-22       Impact factor: 47.728

6.  FAM83H-AS1 is upregulated and predicts poor prognosis in colon cancer.

Authors:  Lei Yang; Jinpeng Cui; Yakun Wang; Jinjing Tan
Journal:  Biomed Pharmacother       Date:  2019-08-19       Impact factor: 6.529

7.  Reconstitution of CPSF active in polyadenylation: recognition of the polyadenylation signal by WDR33.

Authors:  Lars Schönemann; Uwe Kühn; Georges Martin; Peter Schäfer; Andreas R Gruber; Walter Keller; Mihaela Zavolan; Elmar Wahle
Journal:  Genes Dev       Date:  2014-10-09       Impact factor: 11.361

Review 8.  LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms.

Authors:  Eleonora A Braga; Marina V Fridman; Alexey A Moscovtsev; Elena A Filippova; Alexey A Dmitriev; Nikolay E Kushlinskii
Journal:  Int J Mol Sci       Date:  2020-11-23       Impact factor: 5.923

9.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.

Authors:  Bo Li; Eric Severson; Jean-Christophe Pignon; Haoquan Zhao; Taiwen Li; Jesse Novak; Peng Jiang; Hui Shen; Jon C Aster; Scott Rodig; Sabina Signoretti; Jun S Liu; X Shirley Liu
Journal:  Genome Biol       Date:  2016-08-22       Impact factor: 13.583

10.  Sarcopenia and ovarian cancer survival: a systematic review and meta-analysis.

Authors:  Jorne Ubachs; Janine Ziemons; Iris J G Minis-Rutten; Roy F P M Kruitwagen; Jos Kleijnen; Sandrina Lambrechts; Steven W M Olde Damink; Sander S Rensen; Toon Van Gorp
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-08-07       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.